Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 0.25 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Spark Therapeutics.

Burst Expert Illustrations and Commentaries™: Visualizing Gene Therapy Approaches in Hemophilia A

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

This Burst Expert Illustrations and Commentaries™ is a video-based program in which an expert discusses the etiology and emerging treatment of hemophilia A. In this activity, the faculty focuses on the pathophysiology of hemophilia A relevant to the use of gene therapy, which is currently under investigation. This discussion is enriched with the use of video animation to illustrate the mechanism of disease.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Spark Therapeutics.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, pediatricians, and primary care clinicians, medical geneticists, nurses, and other healthcare professionals who care for patients with hemophilia.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Assess the severity of hemophilia A according to clinical presentation and results of factor assays
Analyze the potential impact of emerging therapies on the management of
hemophilia A

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Steven W. Pipe, MD
Professor of Pediatrics and Pathology, Coagulation
Medical Director, Pediatric Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Disclosures: Grant/Research Support: Siemens; Consultant: ApcinteX, ASC Therapeutics, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sangamo Theraputics, Sanofi, Takeda Oncology, Spark Therapeutics, uniQure.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.